Project Grant R03HL171441

Award Date 4/15/24
Completion Date 3/31/26
Dollars Obligated $347K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $274,392 to the University of South Florida to investigate the relationship between social determinants of health (SDOH) and asthma-related morbidity in Black and Latinx adult populations. The research aims to: 1) determine if Black vs. Latinx adults with moderate-severe asthma have unique SDOH exposomes associated with worse asthma outcomes, 2) assess if African...
This Project Grant award of $673,581 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a study by Ochin, Inc. to assess disparities in asthma care between Latino and non-Hispanic white adults. The project aims to leverage a unique national dataset of community health center data linked to social determinants of health information to identify factors underlying any disparities in asthma care utilization. The findings are expected to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $797,130 to The Children's Hospital of Philadelphia (CHOP) from September 2024 to June 2028. The project aims to implement and evaluate the real-world effectiveness of "single maintenance and reliever therapy" (SMART) for managing moderate-to-severe childhood asthma in a predominantly Black pediatric population. The study uses a...
This federal Project Grant award, valued at $154,861 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to advance the integration of social and medical care to promote health equity among children with asthma. The key products and services to be delivered under this grant include: Developing a population-based machine learning model to predict risk of asthma-related hospitalization among children in Washington, D.C. using social...
The Project Grant award K23HL163253, totaling $178,783, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award will support Dr. Pappalardo's research to understand barriers and develop targeted implementation strategies for school-based stock inhaler programs, with the goal of improving asthma management and reducing health disparities. The grant will fund a community-engaged, implementation science...
This federal Project Grant award from the National Institute of Nursing Research (NINR) under CFDA 93.361 - Nursing Research, will support the development and evaluation of IMAAP, an interactive mobile asthma action plan. The $441,375 award, effective July 17, 2024 through May 31, 2026, aims to create an innovative technology that leverages objective lung function assessment, symptom reporting, and personalized treatment recommendations to empower adolescents, particularly those from...
This Cooperative Agreement award of $2,080,912 from the Centers for Disease Control and Prevention (CDC) under the Investigations and Technical Assistance program (CFDA 93.283) will support the Connecticut Department of Public Health's efforts to advance health equity in asthma control. Key activities include: Expanding asthma home visiting programs for high-risk children and adults to reduce emergency department visits and hospitalizations. Developing a network of services to address social...
This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health (CFDA 93.113) federal grant program, provides $704,105 to Brigham & Women's Hospital Inc. to study the impact of multiple long-term environmental exposures on the incidence of asthma. The key objectives are to: (1) determine how exposures like air pollution, temperature, and greenspace are associated with asthma onset; (2) identify demographic, behavioral, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $393,180 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Texas Woman's University (TWU) to develop and validate a self-management questionnaire for adolescents with asthma. The 3-year project aims to create a reliable and valid instrument to assess asthma self-management behaviors and cognitive autonomy in adolescents aged 12-21. The research will involve qualitative and quantitative approaches,...
This Cooperative Agreement awarded by the Centers for Disease Control and Prevention (CDC) under the CDC Investigations and Technical Assistance program (CFDA 93.283) is providing $2,054,187 to Health Research, Inc. to advance health equity in asthma control through the EXHALE strategies. The project period runs from September 1, 2024 to August 31, 2028. Health Research, Inc., a non-profit organization based in New York, will implement this program in partnership with the American Lung...

INVESTIGATING MEDICAID POLICY AND ACCESS TO ASTHMA CARE AND TREATMENT (IMPACT) - PROJECT SUMMARY / ABSTRACT ASTHMA AFFECTS 1 IN 12 U.S. ADULTS AND LEADS TO 1.9 MILLION EMERGENCY DEPARTMENT (ED) VISITS AND 500,000 HOSPITALIZATIONS ANNUALLY. PATIENTS OF LOWER SOCIOECONOMIC STATUS, AS WELL AS MEMBERS OF RACIAL AND ETHNIC MINORITIES, ARE DISPROPORTIONATELY MORE LIKELY TO SUFFER FROM ASTHMA AND EXPERIENCE WORSE HEALTH OUTCOMES. MEDICAID IS THE PRIMARY SOURCE OF HEALTH INSURANCE FOR LOW-INCOME PERSONS. HOWEVER, RATES OF PROVIDER ACCEPTANCE OF MEDICAID INSURANCE REMAIN LOW DUE TO POOR REIMBURSEMENT RATES, RESTRICTING ACCESS TO NEEDED CARE. AT THE SAME TIME, MEDICAID MANAGED CARE PLANS HAVE PROLIFERATED AND NOW ACCOUNT FOR OVER TWO-THIRDS OF MEDICAID ENROLLEES. ONE STRATEGY USED BY MANAGED CARE ORGANIZATIONS TO REDUCE HEALTH COSTS IS TO LIMIT PARTICIPATING PROVIDER NETWORKS TO STEER BENEFICIARIES TO HIGH-VALUE PROVIDERS. WHILE STATE AND FEDERAL POLICY REQUIRE MINIMUM STANDARDS FOR NETWORK ADEQUACY, RECENT EVIDENCE SUGGESTS THAT ACTUAL ACCEPTANCE OF MEDICAID AMONG PROVIDERS MAY BE EVEN LOWER THAN REPORTED. THE EXTENT TO WHICH THESE RESTRICTIVE PROVIDER NETWORKS IMPACT ACCESS TO CARE AMONG MEDICAID BENEFICIARIES WITH ASTHMA AND AFFECT HEALTH OUTCOMES REMAINS UNSTUDIED. WE HAVE ASSEMBLED A MULTI-DISCIPLINARY TEAM WITH EXPERTISE IN ASTHMA OUTCOMES, POLICY EVALUATION, AND CLAIMS ANALYSIS TO EVALUATE MEDICAID PROVIDER NETWORK DENSITY, ACCESS TO PRIMARY AND SPECIALTY CARE, AND ED VISIT AND HOSPITALIZATION RATES AMONG A NATIONAL SAMPLE OF ADULT MEDICAID BENEFICIARIES WITH ASTHMA. WE WILL FIRST CONSTRUCT A CLAIMS-BASED MEASURE OF NETWORK DENSITY FOR EACH MANAGED CARE PLAN BY CALCULATING THE RATIO OF IN-NETWORK PRIMARY CARE PROVIDERS AND SPECIALISTS TO THE NUMBER OF BENEFICIARIES ENROLLED IN EACH MANAGED CARE PLAN (AIM 1). NEXT, WE WILL TEST THE HYPOTHESIS THAT LOWER PROVIDER NETWORK DENSITY IS ASSOCIATED WITH LESS FREQUENT PRIMARY AND SPECIALTY CARE (AIM 2) AND MORE FREQUENT ASTHMA-RELATED ED VISITS AND HOSPITALIZATIONS (AIM 3). THIS WORK BUILDS ON THE PI'S K23 FINDINGS AND WILL SERVE AS CRITICAL PRELIMINARY DATA FOR AN R01 PROPOSAL TO EVALUATE THE IMPACT OF MANAGED CARE AND STATE-LEVEL POLICIES ON ASTHMA OUTCOMES AND HEALTH DISPARITIES, WITH A FOCUS ON ASTHMA PATIENTS IN STRUCTURALLY MARGINALIZED COMMUNITIES. OUR FINDINGS CAN BE USED BY ADVOCATES AND POLICYMAKERS TO ENHANCE STANDARDS FOR NETWORK ADEQUACY AND IMPROVE ACCESS TO CARE AMONG ASTHMA PATIENTS WHO EXPERIENCE HEALTH DISPARITIES.

Posted 4/12/24, 12:00 AM